Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Completed · Phase 3

Conditions studied: Neonatal Sepsis

In brief

This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.

Key facts

Study ID
NCT05856227
Run by
Basilea Pharmaceutica
People needed
9
Starts
2023-08-06
Expected to finish
2024-12-18
Last updated by the study team
2025-07-28

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.